EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Parasitological cure and clinical benefits of benznidazole treatment in patients from the Jequitinhonha Valley, MG, Brazil, with recent chronic infection by Trypanosoma cruzi II

Marta de Lana, Lourena Tomazelli Suave, Júlio César Santoro de Oliveira Assis, Girley Francisco Machado de Assis, Matheus Marques Milagre, Glaucia Diniz Alessio, Renato Afonso Salgado, Olindo Assis Martins-Filho, Pedro Albajar-Viñas, Rosália Morais Torres

Memórias do Instituto Oswaldo Cruz · 2025

DOI: 10.1590/0074-02760240229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Memórias do Instituto Oswaldo Cruz, 2025. Verfasst von Marta de Lana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Universidade Federal de Ouro Preto, Núcleo de Pesquisas em Ciências Biológicas, Programa de Pós-Graduação em Ciências Biológicas, Ouro Preto, MG, Bra…. Hauptthemen laut MEDLINE: Nitroimidazoles, Chagas Disease, Trypanocidal Agents, Trypanosoma cruzi. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, FAPEMIG, CNPq.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND The treatment of the early chronic phase of Chagas disease (CD) may result in high rates of parasitological cure, which may be associated with clinical benefits. OBJECTIVES To evaluate children with CD from the Jequitinhonha Valley, MG, Brazil, treated with benznidazole (BZ), employing classic and alternative methodologies. METHODS Before and after treatment, nine individuals were examined by haemoculture, polymerase chain reaction (PCR), conventional enzyme-linked immunosorbent assay (ELISA), electrocardiogram, echocardiogram, and thoracic and gastrointestinal X-ray. Eight individuals were in the indeterminate clinical form of CD, and one was in the mild cardiac form. After treatment, all individuals were re-evaluated periodically for 4-26 years using the same methodologies cited and anti-live trypomastigotes antibodies by flow-cytometry-FC-ALTA and quantitative PCR (qPCR). FINDINGS The cure rate by the classic cure criteria was 33.33%. By the alternative cure criteria using FC-ALTA and qPCR, the rates of cure were 50% and 78%, respectively. Post-treatment clinical evaluations revealed stability in 5/9 and discrete clinical evolution in 4/9 individuals. MAIN CONCLUSIONS It was demonstrated the effectiveness of BZ treatment in recent chronic infections of CD with low or higher rates of parasitological cure according to the cure criterion used after long-term follow-up. The clinical status of the individuals remained stable or evolved slowly, suggesting clinical benefits from BZ treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitroimidazolesChagas DiseaseTrypanocidal AgentsTrypanosoma cruziHumansChildChronic DiseaseMaleFemaleChild, PreschoolAdolescentEnzyme-Linked Immunosorbent AssayBrazilPolymerase Chain ReactionTreatment OutcomeYoung AdultFlow Cytometry

Substanzen

benzonidazoleNitroimidazolesTrypanocidal Agents

Autor:innen und Institutionen

  • Universidade Federal de Ouro Preto, Núcleo de Pesquisas em Ciências Biológicas, Programa de Pós-Graduação em Ciências Biológicas, Ouro Preto, MG, Brasil.
  • Universidade Federal de Ouro Preto, Programa de Pós-Graduação em Ciências Farmacêuticas, Ouro Preto, MG, Brasil.
  • Universidade Federal de Juiz de Fora, Laboratório de Parasitologia, Governador Valadares, MG, Brasil.
  • Fundação Oswaldo Cruz-Fiocruz, Instituto de Pesquisas René Rachou, Grupo Integrado de Pesquisas em Biomarcadores, Belo Horizonte, MG, Brasil.
  • Hospital Nossa Senhora das Graças, Sete Lagoas, MG, Brasil.
  • World Health Organization, Department of Control of Neglected Tropical Diseases, Geneva, Switzerland.

Förderung

  • World Health Organization
  • FAPEMIG
  • CNPq

Zitieren

APA

de Lana, M., Suave, L. T., Assis, J. C. S. O., de Assis, G. F. M., Milagre, M. M., Alessio, G. D., Salgado, R. A., Martins-Filho, O. A., Albajar-Viñas, P., & Torres, R. M. (2025). Parasitological cure and clinical benefits of benznidazole treatment in patients from the Jequitinhonha Valley, MG, Brazil, with recent chronic infection by Trypanosoma cruzi II. Memórias do Instituto Oswaldo Cruz. https://doi.org/10.1590/0074-02760240229

Vancouver

de Lana M, Suave LT, Assis JCSO, de Assis GFM, Milagre MM, Alessio GD, et al. Parasitological cure and clinical benefits of benznidazole treatment in patients from the Jequitinhonha Valley, MG, Brazil, with recent chronic infection by Trypanosoma cruzi II. Memórias do Instituto Oswaldo Cruz. 2025. doi:10.1590/0074-02760240229

BibTeX
@article{deLana2025,
  author = {de Lana, Marta and Suave, Lourena Tomazelli and Assis, Júlio César Santoro de Oliveira and de Assis, Girley Francisco Machado and Milagre, Matheus Marques and Alessio, Glaucia Diniz and Salgado, Renato Afonso and Martins-Filho, Olindo Assis and Albajar-Viñas, Pedro and Torres, Rosália Morais},
  title = {Parasitological cure and clinical benefits of benznidazole treatment in patients from the Jequitinhonha Valley, MG, Brazil, with recent chronic infection by Trypanosoma cruzi II},
  journal = {Memórias do Instituto Oswaldo Cruz},
  year = {2025},
  doi = {10.1590/0074-02760240229}
}
Kostenlos starten →